Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines.  Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors.  Fusion’s clinical portfolio includes:  FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial;  FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial;  FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial.  In addition, Fusion is pursuing combination programs between RCs and DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for Fusion's growing pipeline of RCs.  

Responsibilities

• AZ/Fusion Portfolio coverage:  This position will cross the AZ/Fusion radioconjugate portfolio.  The candidate will be expected to participate on investigator outreach, site feasibility, SQVs, SIVs and retraining’s as needed.
• Cultivate relationships with clinical trial sites: maintain rapport with investigators in radiology/nuclear medicine physicians, technologists, physicists, radiation safety, medical oncologists and nursing staff to assist with the trial process throughout program development and implementation. Obtain site feedback for potential incorporation into all programs from Phase 1 through commercialization.
• Engage sites at departmental level: understand site working practices and encourage multidisciplinary interactions for success. Ensure clinical teams are informed of site processes and communication lines understood. 
• Collaborating with internal stakeholders: Support internal stake holders by providing tactical input on the patient journey, preparation and administration, storage and destruction of IMP. Assist clinical development programs to meet goals and objectives. Assist with clinical trial site qualification visits, selection process and initiation visits. Create KOL and radioconjugate partners profiling list for use across programs.
• Serve as a resource to investigators and study sites:  Possess a thorough understanding of the FDA, OIG, HIPAA, PhRMA Code and other ethical guidelines relevant to the pharmaceutical industry, to ensure compliance with these external as well as internal guidelines and standard operating procedures.  Be a resource for sites having questions related to the science, investigational theranostics and protocol of ongoing and/or planned clinical trials. 
• Support the development of key interactions with Patient Advocacy Groups: ensure Fusion is introduced and known to applicable advocacy groups. Develop strong working relationships to assist in advancement of Fusion TATs and clinical trials and oversee Fusion support of advocacy groups as appropriate as we grow as an organization.
• Develop educational materials and ensure training of clinical development, clinical operations and MSLs on radioligand therapies, licensures, radiologic/nuclear medicine technology and site practices.
• Maintain RSL Expertise: Detailed knowledge of oncology and nuclear medicine, disease management, medical/clinical research.  Thorough understanding of GCPs and current standards. Remain current with scientific knowledge, maintaining knowledge of pharmaco-economics, coordinating activities with other field personnel in territory.
• Leverage past experiences and relationships to assist in site selection and site evaluation process for potential clinical sites participating in Pharma Fusion clinical trials.
• Assist with Organizing and Participating in Fusion /AZ advisory board meetings.
• Work through complex programs (dosimetry, radiation safety support consultants, radiation license amendments, educate Agreement State(s) and NRC regulators on Alpha therapy.)
• Provide nuclear medicine radiation safety training to Internal and external stakeholders.
• Participate in protocol Safety Review Committee (SRC) meetings as needed.
• Assist with sponsorship requests (SNMMI, ASTRO, EANM, ASCO, ESMO etc.)
• Attend regional, national and international oncology, nuclear medicine, physicians and oncology meetings as needed. 
• Increase AZ/ Fusion radioconjugate awareness in the nuclear medicine, radiation oncology and oncology community.
• Assist with the development of internal Radioconjugate programs.
• Strong problem solving and analytical skills.

Qualifications

•  Advanced Degree, such as a Doctorate of Pharmacy degree (BCOP or BCNP.) Medical Doctor degree or Ph.D. in a research science, is preferred or Advanced Degree with relevant experience. 
• 5+ years experience in oncology and or radiopharmaceutical drug development.
• Scientific and technical expertise, communication skills and business acumen. In pharmaceutical industry language, the RSL role is defined as non-promotional.
• Candidates must have superior interpersonal skills, including the ability to create and sustain relationships with industry leaders. 
• Skilled in clinical research and understand the process of that research and of pharmaceutical product development and approval.
• Ability to be flexible, work independently and prioritize workload.
• Willing to travel domestically and internationally 

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.